

Mondher Toumi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1408355/publications.pdf>

Version: 2024-02-01

127
papers

2,796
citations

186265

28
h-index

223800

46
g-index

133
all docs

133
docs citations

133
times ranked

3724
citing authors

#	ARTICLE	IF	CITATIONS
1	Rates and correlates of employment in people with schizophrenia in the UK, France and Germany. <i>British Journal of Psychiatry</i> , 2007, 191, 30-37.	2.8	294
2	Burden on caregivers of people with schizophrenia: Comparison between Germany and Britain. <i>British Journal of Psychiatry</i> , 2007, 190, 333-338.	2.8	108
3	Advanced therapy medicinal products: current and future perspectives. <i>Journal of Market Access & Health Policy</i> , 2016, 4, 31036.	1.5	97
4	Gene therapies development: slow progress and promising prospect. <i>Journal of Market Access & Health Policy</i> , 2017, 5, 1265293.	1.5	91
5	Correlates of Subjective Quality of Life in People With Schizophrenia. <i>Journal of Nervous and Mental Disease</i> , 2008, 196, 87-94.	1.0	83
6	Challenges in Research and Health Technology Assessment of Rare Disease Technologies: Report of the ISPOR Rare Disease Special Interest Group. <i>Value in Health</i> , 2018, 21, 493-500.	0.3	75
7	Measuring health-related quality of life in young children: how far have we come?. <i>Journal of Market Access & Health Policy</i> , 2019, 7, 1618661.	1.5	72
8	The real-life impact of vaccination on COVID-19 mortality in Europe and Israel. <i>Public Health</i> , 2021, 198, 230-237.	2.9	70
9	Key drivers for market penetration of biosimilars in Europe. <i>Journal of Market Access & Health Policy</i> , 2017, 5, 1272308.	1.5	64
10	Managed Entry Agreements: Policy Analysis From the European Perspective. <i>Value in Health</i> , 2020, 23, 425-433.	0.3	64
11	A prospective study of Quality of life in schizophrenia in three European countries. <i>Schizophrenia Research</i> , 2007, 93, 194-202.	2.0	61
12	Analytic Considerations in Applying a General Economic Evaluation Reference Case to Gene Therapy. <i>Value in Health</i> , 2019, 22, 661-668.	0.3	61
13	Overview of external reference pricing systems in Europe. <i>Journal of Market Access & Health Policy</i> , 2015, 3, 27675.	1.5	60
14	The European Schizophrenia Cohort. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2005, 40, 707-717.	3.1	58
15	Side effects of antipsychotic medication and health-related quality of life in schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , 2009, 119, 22-28.	4.5	54
16	Access to orphan drugs in Europe: current and future issues. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2012, 12, 23-29.	1.4	49
17	Prevalence of hepatitis C infection among the general population and high-risk groups in the EU/EEA: a systematic review update. <i>BMC Infectious Diseases</i> , 2019, 19, 655.	2.9	49
18	Psychosocial functioning, quality of life and clinical correlates of comorbid alcohol and drug dependence syndromes in people with schizophrenia across Europe. <i>Psychiatry Research</i> , 2016, 239, 301-307.	3.3	46

#	ARTICLE	IF	CITATIONS
19	Characteristics of doctor-shoppers: a systematic literature review. <i>Journal of Market Access & Health Policy</i> , 2019, 7, 1595953.	1.5	43
20	Market access agreements for pharmaceuticals in Europe: diversity of approaches and underlying concepts. <i>BMC Health Services Research</i> , 2011, 11, 259.	2.2	42
21	Supply-side and demand-side policies for biosimilars: an overview in 10 European member states. <i>Journal of Market Access & Health Policy</i> , 2017, 5, 1307315.	1.5	39
22	Comparison of NITAG policies and working processes in selected developed countries. <i>Vaccine</i> , 2015, 33, 3-11.	3.8	38
23	Stigma in visible skin diseases – a literature review and development of a conceptual model. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 1493-1504.	2.4	38
24	Urban residence, victimhood and the appraisal of personal safety in people with schizophrenia: results from the European Schizophrenia Cohort (EuroSC). <i>Psychological Medicine</i> , 2008, 38, 591-597.	4.5	37
25	Sipuleucel-T (Provenge®) – Autopsy of an Innovative Paradigm Change in Cancer Treatment: Why a Single-Product Biotech Company Failed to Capitalize on its Breakthrough Invention. <i>BioDrugs</i> , 2015, 29, 301-307.	4.6	36
26	Funding breakthrough therapies: A systematic review and recommendation. <i>Health Policy</i> , 2018, 122, 217-229.	3.0	35
27	Do payers value rarity? An analysis of the relationship between disease rarity and orphan drug prices in Europe. <i>Journal of Market Access & Health Policy</i> , 2017, 5, 1299665.	1.5	31
28	Meta-analysis of real-world evidence comparing non-vitamin K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation. <i>Journal of Market Access & Health Policy</i> , 2019, 7, 1574541.	1.5	31
29	Chinese guidelines related to novel coronavirus pneumonia. <i>Journal of Market Access & Health Policy</i> , 2020, 8, 1818446.	1.5	31
30	Association between social contact frequency and negative symptoms, psychosocial functioning and quality of life in patients with schizophrenia. <i>Psychiatry Research</i> , 2015, 230, 860-866.	3.3	29
31	Filling the gap in CNS drug development: evaluation of the role of drug repurposing. <i>Journal of Market Access & Health Policy</i> , 2017, 5, 1299833.	1.5	28
32	Direct medical mental health care costs of schizophrenia in France, Germany and the United Kingdom – Findings from the European Schizophrenia Cohort (EuroSC). <i>European Psychiatry</i> , 2009, 24, 216-224.	0.2	27
33	Patient survey to identify reasons for non-adherence and elicitation of quality of life concepts associated with immunosuppressant therapy in kidney transplant recipients. <i>Patient Preference and Adherence</i> , 2016, 10, 27.	1.8	25
34	Regenerative medicine regulatory policies: A systematic review and international comparison. <i>Health Policy</i> , 2020, 124, 701-713.	3.0	24
35	A comparative study of orphan drug prices in Europe. <i>Journal of Market Access & Health Policy</i> , 2017, 5, 1297886.	1.5	23
36	The Use of Surrogate and Patient-Relevant Endpoints in Outcomes-Based Market Access Agreements. <i>Applied Health Economics and Health Policy</i> , 2017, 15, 5-11.	2.1	22

#	ARTICLE	IF	CITATIONS
37	A prospective study of health care resource utilisation and selected costs of schizophrenia in France. BMC Health Services Research, 2012, 12, 269-76.	2.2	21
38	A comparison of HAS & NICE guidelines for the economic evaluation of health technologies in the context of their respective national health care systems and cultural environments. Journal of Market Access & Health Policy, 2015, 3, 24966.	1.5	20
39	Market access of gene therapies across Europe, USA, and Canada: challenges, trends, and solutions. Drug Discovery Today, 2021, 26, 399-415.	6.4	20
40	New drug regulations in France: what are the impacts on market access? Part 1 " Overview of new drug regulations in France. Journal of Market Access & Health Policy, 2013, 1, 20891.	1.5	19
41	The perverse impact of external reference pricing (ERP): a comparison of orphan drugs affordability in 12 European countries. A call for policy change. Journal of Market Access & Health Policy, 2017, 5, 1369817.	1.5	19
42	Residential area and social contacts in schizophrenia. Social Psychiatry and Psychiatric Epidemiology, 2007, 42, 617-622.	3.1	18
43	Design of Patient Access Schemes in the UK. Applied Health Economics and Health Policy, 2011, 9, 209-215.	2.1	18
44	Relapse according to antipsychotic treatment in schizophrenic patients: a propensity-adjusted analysis. BMC Psychiatry, 2011, 11, 24.	2.6	18
45	Clinical management and associated costs for moderate and severe Alzheimer's disease in urban China: a Delphi panel study. Translational Neurodegeneration, 2015, 4, 15.	8.0	18
46	Impact of patient characteristics and treatment procedures on hospitalization cost and length of stay in Japanese patients with influenza: A structural equation modelling approach. Influenza and Other Respiratory Viruses, 2017, 11, 543-555.	3.4	18
47	Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with vitamin K antagonists in patients with nonvalvular atrial fibrillation: a systematic literature review. Expert Review of Pharmacoeconomics and Outcomes Research, 2019, 19, 27-36.	1.4	18
48	Health economic evaluation of gene replacement therapies: methodological issues and recommendations. Journal of Market Access & Health Policy, 2020, 8, 1822666.	1.5	18
49	Analysis of health economics assessment reports for pharmaceuticals in France " understanding the underlying philosophy of CEESP assessment. Journal of Market Access & Health Policy, 2017, 5, 1344088.	1.5	17
50	Capturing the value of vaccination within health technology assessment and health economics: Country analysis and priority value concepts. Vaccine, 2022, 40, 3999-4007.	3.8	17
51	Determining the value of medical technologies to treat ultra-rare disorders: a consensus statement. Journal of Market Access & Health Policy, 2016, 4, 33039.	1.5	16
52	Economic burden for Alzheimer's disease in China from 2010 to 2050: a modelling study. Journal of Market Access & Health Policy, 2019, 7, 1667195.	1.5	15
53	Factors influencing the COVID-19 daily deaths' peak across European countries. Public Health, 2021, 194, 135-142.	2.9	14
54	Current process and future path for health economic assessment of pharmaceuticals in France. Journal of Market Access & Health Policy, 2015, 3, 27902.	1.5	13

#	ARTICLE	IF	CITATIONS
55	Unlocking the potential of established products: toward new incentives rewarding innovation in Europe. <i>Journal of Market Access & Health Policy</i> , 2017, 5, 1298190.	1.5	13
56	Patient preference for chronic obstructive pulmonary disease (COPD) treatment inhalers: a discrete choice experiment in France. <i>Current Medical Research and Opinion</i> , 2019, 35, 785-792.	1.9	13
57	Comparative efficacy of subcutaneous (CT-P13) and intravenous infliximab in adult patients with rheumatoid arthritis: a network meta-regression of individual patient data from two randomised trials. <i>Arthritis Research and Therapy</i> , 2021, 23, 119.	3.5	13
58	Vaccine market access pathways in the EU27 and the United Kingdom – analysis and recommendations for improvements. <i>Vaccine</i> , 2021, 39, 5706-5718.	3.8	13
59	Determinants of orphan drugs prices in France: a regression analysis. <i>Orphanet Journal of Rare Diseases</i> , 2017, 12, 75.	2.7	12
60	The mediating role of depression in pathways linking positive and negative symptoms in schizophrenia. A longitudinal analysis using latent variable structural equation modelling. <i>Psychological Medicine</i> , 2020, 50, 566-574.	4.5	12
61	Capturing the value of vaccination within health technology assessment and health economics: Literature review and novel conceptual framework. <i>Vaccine</i> , 2022, 40, 4008-4016.	3.8	12
62	Which Criteria are Considered and How are They Evaluated in Health Technology Assessments? A Review of Methodological Guidelines Used in Western and Asian Countries. <i>Applied Health Economics and Health Policy</i> , 2021, 19, 281-304.	2.1	11
63	Variation in market access decisions for cell and gene therapies across the United States, Canada, and Europe. <i>Health Policy</i> , 2021, 125, 1550-1556.	3.0	11
64	Drug repurposing in pharmaceutical industry and its impact on market access: market access implications. <i>Journal of Market Access & Health Policy</i> , 2014, 2, 22814.	1.5	10
65	The impact of COVID-19 on the cell and gene therapies industry: Disruptions, opportunities, and future prospects. <i>Drug Discovery Today</i> , 2021, 26, 2269-2281.	6.4	10
66	Drug pricing reform in China: analysis of piloted approaches and potential impact of the reform. <i>Journal of Market Access & Health Policy</i> , 2016, 4, 30458.	1.5	9
67	Antithrombotic Treatments in Patients with Chronic Coronary Artery Disease or Peripheral Artery Disease: A Systematic Review of Randomised Controlled Trials. <i>Cardiovascular Therapeutics</i> , 2020, 2020, 1-11.	2.5	9
68	Commentary on ‘Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial’ by Gautret et al. <i>Journal of Market Access & Health Policy</i> , 2020, 8, 1758390.	1.5	9
69	On the association between SARS-COV-2 variants and COVID-19 mortality during the second wave of the pandemic in Europe. <i>Journal of Market Access & Health Policy</i> , 2021, 9, 2002008.	1.5	9
70	Assessing the Value of Nusinersen for Spinal Muscular Atrophy: A Comparative Analysis of Reimbursement Submission and Appraisal in European Countries. <i>Frontiers in Pharmacology</i> , 2021, 12, 750742.	3.5	9
71	Recommendations for strengthening NITAG policies in developed countries. <i>Vaccine</i> , 2015, 33, 1-2.	3.8	8
72	Cost-effectiveness of bedaquiline in MDR and XDR tuberculosis in Italy. <i>Journal of Market Access & Health Policy</i> , 2017, 5, 1283105.	1.5	8

#	ARTICLE	IF	CITATIONS
73	Healthcare resource use in schizophrenia, EuroSC findings. Journal of Market Access & Health Policy, 2017, 5, 1372027.	1.5	8
74	Health related quality of life in patients having schizophrenia negative symptoms – a systematic review. Journal of Market Access & Health Policy, 2018, 6, 1517573.	1.5	8
75	Primary cesarean delivery rate: Potential impact of a checklist. Journal of Gynecology Obstetrics and Human Reproduction, 2018, 47, 419-424.	1.3	8
76	Systematic review of utility values used in the pharmacoeconomic evaluations for schizophrenia: implications on cost-effectiveness results. Journal of Market Access & Health Policy, 2019, 7, 1648973.	1.5	8
77	Patient Reported Outcomes Instruments in Schizophrenia: A Review of Psychometric Properties. Open Journal of Medical Psychology, 2014, 03, 141-156.	0.5	8
78	Quantifying the persisting orphan-drug shortage public health crisis in the United States. Journal of Market Access & Health Policy, 2017, 5, 1269473.	1.5	7
79	Patient-reported outcome claims in European and United States orphan drug approvals. Journal of Market Access & Health Policy, 2018, 6, 1542920.	1.5	7
80	Impact of methodological choices on a meta-analysis of real-world evidence comparing non-vitamin-K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation. Current Medical Research and Opinion, 2019, 35, 1867-1872.	1.9	7
81	Health-related quality of life of patients after ischaemic stroke treated in a provincial hospital in Poland. Journal of Market Access & Health Policy, 2020, 8, 1775933.	1.5	7
82	Systematic Review of Health State Utility Values Used in European Pharmacoeconomic Evaluations for Chronic Hepatitis C: Impact on Cost-Effectiveness Results. Applied Health Economics and Health Policy, 2021, 19, 29-44.	2.1	7
83	Patient-Reported Outcomes in Oncology, Beyond Randomized Controlled Trials. Recent Results in Cancer Research, 2019, 213, 57-65.	1.8	7
84	Health Technology Assessment of Gene Therapies in Europe and the USA: Analysis and Future Considerations. Cell & Gene Therapy Insights, 2019, 5, 1043-1059.	0.1	7
85	Amortization of gene replacement therapies: A health policy analysis exploring a mechanism for mitigating budget impact of high-cost treatments. Health Policy, 2022, 126, 49-59.	3.0	7
86	Conflict of interest in Health Technology Assessment decisions: case law in France and impact on reimbursement decisions. Journal of Market Access & Health Policy, 2015, 3, 25682.	1.5	6
87	Memantine for treatment of moderate or severe Alzheimer’s disease patients in urban China: clinical and economic outcomes from a health economic model. Expert Review of Pharmacoeconomics and Outcomes Research, 2015, 15, 565-578.	1.4	6
88	Non-profit Drug Research and Development at a Crossroads. Pharmaceutical Research, 2018, 35, 52.	3.5	6
89	Systematic review of pharmacoeconomic models for schizophrenia. Journal of Market Access & Health Policy, 2018, 6, 1508272.	1.5	6
90	Improved Therapeutic Approaches are Needed to Manage Graft-versus-Host Disease. Clinical Drug Investigation, 2021, 41, 929-939.	2.2	6

#	ARTICLE	IF	CITATIONS
91	An overview of health technology assessments of gene therapies with the focus on cost-effectiveness models. <i>Journal of Market Access & Health Policy</i> , 2021, 9, 2002006.	1.5	6
92	Evaluating the burden of pruritus due to atopic dermatitis in Japan by patient-reported outcomes. <i>Journal of Medical Economics</i> , 2021, 24, 1280-1289.	2.1	6
93	Fixing the Price of the Orphan Drug Siklos [®] : The Council of State Takes over the Decision. <i>European Journal of Health Law</i> , 2014, 21, 505-515.	0.2	5
94	National Immunization Therapeutic Advisory Group: it is time for experience sharing and best practice learning. <i>Journal of Market Access & Health Policy</i> , 2015, 3, 29276.	1.5	5
95	No correlation between the prices of oncology orphan drugs in the US and their patient population sizes. <i>Journal of Cancer Policy</i> , 2017, 14, 1-4.	1.4	5
96	Non-profit drug research and development: the case study of Genethon. <i>Journal of Market Access & Health Policy</i> , 2019, 7, 1545514.	1.5	5
97	Orphan Drugs in Oncology. <i>Recent Results in Cancer Research</i> , 2019, 213, 109-142.	1.8	5
98	Current state of developing advanced therapies for rare diseases in the European Union. <i>Expert Opinion on Orphan Drugs</i> , 2020, 8, 417-429.	0.8	5
99	Challenges in the market access of regenerative medicines, and implications for manufacturers and decision-makers: a systematic review. <i>Regenerative Medicine</i> , 2022, 17, 119-139.	1.7	5
100	Gene Therapy Evidence Generation and Economic Analysis: Pragmatic Considerations to Facilitate Fit-for-Purpose Health Technology Assessment. <i>Frontiers in Public Health</i> , 2022, 10, 773629.	2.7	5
101	Validation of disease states in schizophrenia: comparison of cluster analysis between US and European populations. <i>Journal of Market Access & Health Policy</i> , 2016, 4, 30725.	1.5	4
102	Low rates of patient-reported outcome claims for orphan drugs approved by the us food and drug administration. <i>Journal of Market Access & Health Policy</i> , 2018, 6, 1433426.	1.5	4
103	Considering potential solutions for limitations and challenges in the health economic evaluation of gene therapies. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021, 21, 1145-1158.	1.4	4
104	Longitudinal symptomatic interactions in long-standing schizophrenia: a novel five-point analysis based on directed acyclic graphs. <i>Psychological Medicine</i> , 2023, 53, 1371-1378.	4.5	4
105	Risk of discontinuation of Advanced Therapy Medicinal Products clinical trials. <i>Journal of Market Access & Health Policy</i> , 2016, 4, 32232.	1.5	3
106	Oncology from an HTA and Health Economic Perspective. <i>Recent Results in Cancer Research</i> , 2019, 213, 25-38.	1.8	3
107	Towards a more transparent HTA process in Poland: new Polish HTA methodological guidelines. <i>Journal of Market Access & Health Policy</i> , 2017, 5, 1355202.	1.5	2
108	A tolerability burden index in schizophrenia: incorporating patient perspective in clinical trial adverse event reporting. <i>Journal of Market Access & Health Policy</i> , 2017, 5, 1372026.	1.5	2

#	ARTICLE	IF	CITATIONS
109	PRM44 - DIFFERENTIATING DISCOUNT RATES IN COST-EFFECTIVENESS EVALUATIONS IN THE CONTEXT OF GENE THERAPIES.. Value in Health, 2018, 21, S363.	0.3	2
110	President Trump's prescription to reduce drug prices: from the campaign trail to American Patients First. Journal of Market Access & Health Policy, 2019, 7, 1579597.	1.5	2
111	Heterogeneous Recommendations for Oncology Products Among Different HTA Systems: A Comparative Assessment. Recent Results in Cancer Research, 2019, 213, 39-55.	1.8	2
112	Gene therapy randomised clinical trials in Europe – a review paper of methodology and design. Journal of Market Access & Health Policy, 2020, 8, 1847808.	1.5	2
113	Point-of-care test screening versus Case finding for paediatric coeliac disease: A pragmatic study in primary care. Acta Paediatrica, International Journal of Paediatrics, 2021, 110, 337-339.	1.5	2
114	Allocating treatment resources for hepatitis C in the UK: a constrained optimization modelling approach. Journal of Market Access & Health Policy, 2021, 9, 1887664.	1.5	2
115	An Overview of Cell and Gene Therapy Development in China. Human Gene Therapy, 2021, , .	2.7	2
116	Second opinions, multiple physician appointments, and overlapping prescriptions in the paediatric population: A systematic literature review. Journal of Evaluation in Clinical Practice, 2020, 26, 1761-1767.	1.8	2
117	The diversity in regenerative medicines regulations in Europe, USA and Japan. Cell & Gene Therapy Insights, 2019, 5, 1031-1042.	0.1	2
118	Reinforcing Collaboration and Harmonization to Unlock the Potentials of Advanced Therapy Medical Products: Future Efforts Are Awaited From Manufacturers and Decision-Makers. Frontiers in Public Health, 2021, 9, 754482.	2.7	2
119	Influence of positive and negative symptoms on hedonic and eudaemonic well-being in people with schizophrenia: A longitudinal analysis from the EuroSc study. Schizophrenia Research, 2022, 244, 21-28.	2.0	2
120	PRM116 - GENERAL PERCEPTIONS OF INNOVATIVE METHODS FOR SURVIVAL EXTRAPOLATION IN ONCOLOGY AMONG HTA IN EUROPE, CANADA AND AUSTRALIA. Value in Health, 2018, 21, S375-S376.	0.3	1
121	PRM146 - CURRENT AND FUTURE TRENDS IN METHODOLOGIES OF SURVIVAL CURVE EXTRAPOLATION IN ONCOLOGY ACCEPTED BY HTA AUTHORITIES.. Value in Health, 2018, 21, S381.	0.3	1
122	Why "American Patients First" is likely to raise drug prices outside of the United States. Journal of Market Access & Health Policy, 2019, 7, 1650596.	1.5	1
123	PNS12 FACTORS TO BE CONSIDERED TO ENSURE ACCEPTABILITY OF HISTORICALLY CONTROLLED STUDIES BY HTA BODIES. Value in Health, 2019, 22, S764-S765.	0.3	1
124	A critical analysis and review of Lancet COVID-19 hydroxychloroquine study. Journal of Market Access & Health Policy, 2020, 8, 1809236.	1.5	1
125	About the advantages and disadvantages of discrete-event simulation for health economic analyses. Expert Review of Pharmacoeconomics and Outcomes Research, 2016, 16, 651-652.	1.4	0
126	Partnership agreements for regenerative medicines: a database analysis and implications for future innovation. Regenerative Medicine, 2021, 16, 733-755.	1.7	0

#	ARTICLE	IF	CITATIONS
127	Systematic literature review on implicit factors influencing the HTA deliberative processes in Europe. Journal of Market Access & Health Policy, 2022, 10, .	1.5	0